HIF, Hypoxia Research & Stem Cell News

Stem Cell Company Presents Findings Of Adult Stem Cell Safety And Feasibility Study

DaVinci Biosciences LLC, of Costa Mesa, CA, announced today the presentation of their safety and feasibility study demonstrating the administration of autologous bone marrow derived stem cells for the treatment of acute and chronic spinal cord injury at Neuroscience 2009, Society for Neuroscience’s 39th Annual Meeting, to be held at McCormick Convention Center in Chicago, IL. Rafael Gonzalez, Ph.D., Director of Research and Development for DaVinci Biosciences LLC will present the work during the conference on October 20, 2009 and be available to answer questions regarding the study, following his presentation.

“We are excited to share the findings of this study in such a public forum. This study successfully demonstrates not only the safety and feasibility of using autologous adult stem cells for treating spinal cord injuries, but also that the clinical procedure for delivering these cells is safe as well,” said Dr. Gonzalez.

The abstract highlights data from 8 patients that underwent the treatment which used stem cells harvested from the patients’ own bone marrow to side step any immune rejection response, and features the documented evaluations from a 2 year post surgical follow up period. Furthermore, it illustrates new data obtained from 46 patients that participated in the study using stem cells harvested from the patients’ own bone marrow. Magnetic resonance imaging data of the spinal cord, obtained from those who were treated, shows morphological changes within the damaged areas. In addition, this study documents the improved function of bladder control, ASIA motor scoring and Barthel scoring.

“Although this study was successful, we will build upon the results that we have achieved and the methods we have developed to progress into a larger clinical program. Responsibly, but timely developing ways to improve the quality of life for those affected with injuries or diseases, such as spinal cord injury, is the core of our mission and we are optimistic about the opportunity of conducting future studies in the US,” said Dr. Gonzalez.

from http://www.dvbiosciences.com/

Related posts:

• SALVADOR DE BAHIA (BRAZIL) – Adult Stem Cells Used to Treat Diseased Livers

  Human adult stem cells are being used to cure cirrhosis and other serious live diseases. Another 15 people in Brazil on the liver transplant waiting list have been treated by

• PluristemBegins Enrollment in U.S. With Unmatched Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
  Pluristem Therapeutics Inc. today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company`s
• Excellent Stem Cell Mobilization and Safety Profile for TG-0054
  TaiGen Biotechnology Co., Ltd. announced today that in a phase 1 study in healthy volunteers TG-0054, a chemokine receptor CXCR4 antagonist, was well tolerated and rapidly mobilized stem cells and
• SANUWAVE’S PACE Shows Promise In Stimulating Autogenous Sources Of Progenitor/STEM Cells For Harvest And Re-Transplantation In Bone Tissue Engineering
  SANUWAVE Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific
• Piloting stem cells presents a challenge for treatments
  Image via Wikipedia

  Complications and unanticipated side-effects that have slowed the progression of stem cell studies from the lab to the clinic could soon change, researchers say.
  For a decade, stem cells

If you need more information about STEM CELLS please visit Latest Stem Cells News

This post comes from Latest Stem Cells News
(Digital Fingerprint: 0f6d53ed7d5f01118cf01c21fc9b9d58)